Views:32 Author:Site Editor Publish Time: 2020-03-30 Origin:Site
With the spread of the new crown epidemic on a global scale, China's treatment experience has also been promoted overseas. At a press conference held by the State Council ’s joint prevention and control mechanism on March 17, Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, said that key drugs such as fapilavir, recovery plasma, and Chinese medicine have been provided to the countries involved in the outbreak. However, the specific types of Chinese medicine provided were not disclosed in detail.
Traditional Chinese medicine therapy is sought after in the treatment of new crowns. On March 10th, in the "New Coronary Virus Pneumonia Diagnosis and Treatment Scheme (Trial Implementation Seventh Edition)" issued by the National Health and Medical Commission and the State Administration of Traditional Chinese Medicine, the lotus cleansing pestilence, Huoxiangzhengqi, Jinhuaqinggan granules, Angong Niuhuang Wan The proprietary medicines continue to be listed.
At the same time, the demand for overseas Chinese medicine has also increased significantly. Reuters reported on March 10 that Chinese herbal medicine shops in two major cities, New York and San Francisco, were in short supply. A Chinese medicine doctor said in an interview that the demand for Chinese herbal medicine in its clinic had surged, honeysuckle and isatis granules became best-selling products, and prices were rising rapidly .
According to the Shanghai Securities News, the two traditional Chinese medicines of Yiling Pharmaceutical's Lotus Qingwen and Juxiechang's Jinhua Qinggan have been assisted by Chinese medical experts in Italy, Iraq and other countries.
With the warming up of Chinese herbal medicines going abroad, some investors began to ask listed companies about the export of Chinese herbal medicines such as Banlangen and honeysuckle.
On March 13, China Resources Sanjiu stated on the investor relations interactive platform that the company's overseas business accounted for a very small proportion of the company's overall business, and Banlangen had a small amount of export business (part of the recent exports were used for donations). With the effective control of the new crown pneumonia epidemic situation in China, the epidemic situation in overseas countries is becoming increasingly severe, and the company has been studying the opportunities of expanding the overseas market with varieties such as Chinese medicine formula granules.
However, in fact, on January 21, the official Weibo Health China of the National Health Commission has rumored that Banlangen is used for the prevention of new crown pneumonia. Zhang Ye, chief physician of the Department of Respiratory Medicine at Hepingli Hospital, said that Banlangen is suitable for the treatment of wind and cold, The treatment of febrile diseases such as viral influenza has certain antiviral effects, but it is not effective against coronavirus.
During the outbreak of the SARS epidemic in 2003, Banlangen became famous. As a concept of the epidemic, whenever a pandemic emerges, it will trigger a panic buying. The interface journalist searched the Banlangen drug related situation on the website of the State Drug Administration and showed a total of 1251 records. Pharmaceutical Rubik's Cube previously reported that in 2017 there were 726 domestic manufacturers of Banlangen granules, in addition to various dosage forms such as syrups, soft capsules, effervescent tablets, chewable tablets, and dispersible tablets.
However, the raw material of Banlangen granules, Banlangen decoction pieces, has been the hardest hit area for substandard decoction pieces. In February 2017, the former State Administration of Food and Drug Administration issued the “Notice of 54 General Administration of Chinese Medicine Defective Pieces Disqualified (2017 No. 21)” It shows that of the 54 batches of unqualified Chinese medicine decoction pieces, the number of failed Banlangen is 28 batches, accounting for more than half.
In March 2018, the National Pharmacopoeia Commission issued the "Public Notice on the Proposed Addition and Revision of Banlangen Granule Quality Standards", which revised the method and identification of Banlangen granules and added content determination items.
Although the revision of the standard of Isatis root particles has promoted the improvement of the quality of Isatis root particles, it has also brought about a new round of price increases for Isatis root particles. However, the dispute over the efficacy of Banlangen has not fallen from SARS to today.